SCHEMBL30730685

SCHEMBL30730685

Cc1noc(CC(=O)N2CCC(c3nc(C4(C)CCCCC4)no3)CC2)n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.40
KDM1A O60341 1/20 0.38
LMNA P02545 2/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
EPHX2 P34913 1/20 0.38
SMO Q99835 2/20 0.38
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
FAAH O00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730487 0.84 HSD11B1 (0.39) HSD11B1KDM1ALMNAALOX15TSHR
SCHEMBL30730600 0.84 PKM (0.42) KDM1ALMNAALOX15TSHRMAPK1
SCHEMBL30730464 0.83 HSD11B1 (0.46) HSD11B1LMNAALOX15TSHRMAPK1
SCHEMBL30730629 0.82 HSD11B1 (0.44) HSD11B1LMNAALOX15TSHRMAPK1
SCHEMBL32676637 0.81 HSD11B1 (0.39) HSD11B1LMNAALOX15TSHRMAPK1
SCHEMBL30730456 0.80 HSD11B1 (0.40) HSD11B1LMNAALOX15TSHRMAPK1
SCHEMBL30730620 0.79 HSD11B1 (0.38) HSD11B1LMNAALOX15TSHRMAPK1
SCHEMBL32677041 0.78 LMNA (0.40) HSD11B1LMNAALOX15TSHRMAPK1
SCHEMBL32677069 0.77 LMNA (0.39) HSD11B1LMNAALOX15TSHRMAPK1
SCHEMBL30730712 0.77 HSD11B1 (0.42) HSD11B1TSHRMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 HSD11B1 235/4885KDM1A 4764/4885LMNA 1838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.